MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 267.8% in October

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 1,260,000 shares, a growth of 267.8% from the October 15th total of 342,600 shares. Approximately 12.7% of the company’s stock are short sold. Based on an average daily volume of 2,080,000 shares, the short-interest ratio is currently 0.6 days.

MIRA Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRA traded down $0.04 during midday trading on Wednesday, hitting $1.56. 663,127 shares of the stock were exchanged, compared to its average volume of 2,229,775. MIRA Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $6.40. The business’s fifty day simple moving average is $1.34 and its two-hundred day simple moving average is $1.28. The company has a market capitalization of $23.06 million, a PE ratio of -2.79 and a beta of 3.09.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities analysts anticipate that MIRA Pharmaceuticals will post -0.6 EPS for the current year.

Institutional Trading of MIRA Pharmaceuticals

An institutional investor recently raised its position in MIRA Pharmaceuticals stock. Virtu Financial LLC boosted its holdings in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 330.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 63,055 shares of the company’s stock after buying an additional 48,397 shares during the quarter. Virtu Financial LLC owned about 0.43% of MIRA Pharmaceuticals worth $69,000 at the end of the most recent quarter. Institutional investors and hedge funds own 35.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MIRA shares. Rodman & Renshaw started coverage on MIRA Pharmaceuticals in a report on Monday, September 30th. They issued a “buy” rating and a $17.00 target price for the company. Ascendiant Capital Markets started coverage on MIRA Pharmaceuticals in a report on Monday, August 5th. They issued a “buy” rating and a $11.00 target price for the company. Finally, RODMAN&RENSHAW upgraded MIRA Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.